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Background: Recent studies have been explained the role of lipoxygenases (LOX) in the origin of cancer. Among the
lipoxygenases, the 5-LOX, 12-LOX and 15-LOX are more important in the cause of neoplastic disorders. In the present
investigation, a new series of anticancer agents with 1,3,4-thiadiazole and phthalimide substructures were synthesized and
their in vitro cytotoxicity was evaluated by MTT assay. Moreover, enzyme inhibitory potency was also assessed by enzymatic
protocol towards 15-LOX-1. Molecular docking was performed to explore in silico binding mode of the target compounds.
Results: Tested compounds showed a better cytotoxic activity against HT29 cell line (colorectal cancer) in comparison
with other cell lines (PC3: prostate carcinoma; SKNMC: neuroblastoma). Unfortunately, all of the tested derivatives
rendered lower inhibitory potency than quercetin towards 15-LOX-1. Four hydrogen bonds were detected in docking
studies for compound 4d as the most potent derivative in enzymatic assay.
Conclusions: The biological results of reported compounds in this research were not so satisfactory. But, further
structural modifications are necessary to improve the bioactivity of these derivatives.
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Arachidonic acid is a fatty acid released from membrane
phospholipids during cell stimulation. Arachidonic acid is
metabolized mainly by two groups of enzymes consist of
lipoxygenases (LOX, which includes 5-LOX, 12-LOX, and
15-LOX) and cyclooxygenase (COX). Inhibition of cycloox-
ygenases delays tumorigenesis in animals and humans
[1, 2]. Various epidemiological and animal studies have
confirmed that there is a close relationship between high
fat consumption with an increased incidence and growth of
tumors at several specific organ sites like breast. More re-
cent studies also presented that patients with consumption
of diets with a high proportion of polyunsaturated ω-6 fatty
acid (n-6 PUFA), such as arachidonic acid and linoleic acid
are associated with a more advanced disease stage at the* Correspondence: aliabadi.alireza@gmail.com
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creativecommons.org/publicdomain/zero/1.0/time of diagnosis of breast cancer [2]. The LOXs convert
polyunsaturated fatty acids like arachidonic and linoleic
acids into biologically active metabolites that affects various
cellular events such as signaling, structure and metabolism.
According to the later tumorigenesis studies, it is likely that
polyunsaturated fatty acids may enhance tumorigenesis via
oxidative metabolism. Eicosanoids derived from the arachi-
donic acid cascade have been implicated in the pathogen-
esis of a variety of human diseases, including cancer, and
are now believed to play important roles in tumor promo-
tion, progression, and metastatic disease [3–5]. Vigorous
expression of the enzymes (LOXs & COXs) that synthesize
bioactive lipid metabolites from unsaturated fatty acids
(arachidonic acid and linoleic acid) appears to be related to
the development of prostate carcinoma remarkably. Other
research have also reported that 15-LO-2 is expressed in
normal prostate tissue, but poorly expressed in pros-
tate tumors. Thus, 15-LO-1 is highly expressed in
prostate tumors while 15-LO-2 is highly expressed in
normal tissue. 15-LO-1 in prostate cancer tumorsarticle distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
. The Creative Commons Public Domain Dedication waiver (http://
) applies to the data made available in this article, unless otherwise stated.
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hydroxy-octadecadienoic acid (13-(S)-HODE) and other
metabolites. These metabolites appear to alter cellular sig-
naling pathways, and thus the inappropriate expression
might alter biological events and contribute to tumor
development [6–8]. On the basis of this information,
the drugs with capability of interaction with pathways
related to the production of lipoxygenases metabolites
or signaling functions of lipoxygenases products may
be effective pharmaceutical agents in prevention or
treatment of cancer.
Literature reviews declare that 1,3,4-thiadiazole ring as
5-membered heterocycle have diverse biological effects
such as anti-inflammatory, anticonvulsant, antibacterial,
antileshmanial, antioxidant and anticancer [9–20]. On
the other hands, phthalimide moiety is another hetero-
cyclic residue derived from the isoindole ring. This moi-
ety has also exhibited several pharmacological activities
like anticonvulsant, antitubercular, anti-inflammatory,
anti-acetylcholinesterase as well as anticancer effects
[21–31]. In the current investigation, we encouraged to
synthesize a new series of chemical entities bearing
1,3,4-thiadiazole and phthalimide (isoindoline-1,3-dione)
residues as potential anticancer agents.
Methods
Chemistry
The corresponding chemical reagents and starting mate-
rials were purchased from the commercial companiesScheme 1 Synthetic pathway for preparation of compounds 4a-4 lsuch as Merck and Sigma-Aldrich. The purification of
the prepared compounds was carried out by column
chromatography using ethyl acetate/petroleum ether.
Spectroscopic methods were applied for characterization
of the synthesized compounds. 1H NMR spectra were
acquired by Bruker 250 MHz in deutrated chloroform
(CDCl3) and the obtained data were expressed as δ
(ppm) compared to tetramethylsilane (TMS) as internal
standard. Infrared (IR) spectra of the prepared com-
pounds were obtained by Shimadzu 470 with preparing
potassium bromide (KBr) disk. The mass spectra were
run on a Finigan TSQ-70 spectrometer (Finigan, USA)
at 70 eV. Melting points were determined using electro-
thermal 9001 melting point analyzer apparatus and are
uncorrected.
Synthesis of 2-(1,3-Dioxoisoindolin-2-yl)acetic acid (2)
5 g (33.8 mmol) of phthalic anhydride, 2.53 g
(33.8 mmol) glycine and 4.67 ml (33.8 mmol) triethyla-
mine (Et3N) were mixed in toluene (100 ml) and the re-
action mixture was refluxed overnight (Scheme 1). The
reaction was monitored by thin layer chromatography
(TLC). Toluene was evaporated by rotary evaporator ap-
paratus under reduced pressure. The obtained residue
was washed by diethyl ether (Et2O) and n-hexane. The
obtained white powder was used for the next step with-
out any extra purification [32].
1HNMR (CDCl3, 250 MHz) δ (ppm): 4.3 (s, 2H, −CH2-),
7.70 (dd, 2H, J = 8.4 Hz, J = 2.4 Hz, H5,6-Phthalimide), 7.85
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(brs, −COOH). IR (KBr, cm−1) ῡ: 3468 (OH, acid), 3155,
2989, 2939, 1705 (C = O, acid). MS (m/z, %): 205
(M+, weak), 160 (100), 133 (20), 104 (40), 76 (35), 50 (20).Synthesis of 2-(1,3-Dioxoisoindolin-2-yl)-N-(5-mercapto-
1,3,4-thiadiazol-2-yl)acetamide (3)
3 g (14.63 mmol) of 2-(1,3-dioxoisoindolin-2-yl)acetic
acid (compound 2), 2.80 g (14.63 mmol) N-ethyl-N-
dimethylaminopropyl carbodiimide (EDC) and 1.98 g
(14.63 mmol) hydroxybenzotriazole (HOBt) were mixed
in 70 ml acetonitrile (CH3CN) and the obtained mixture
was stirred for 30 min. Then, 1.95 g (14.63 mmol) of 5-
amino-1,3,4-thiadiazole-2-thiol was added to the reac-
tion mixture and the stirring was continued for 24 h.
The reaction end was proved by thin layer chromatog-
raphy (TLC). Then, acetonitrile was evaporated using ro-
tary evaporator and the residue was washed by diethyl
ether and n-hexane. More purification was done by col-
umn chromatogaraphy (petroleum ether/ethyl acetate
70/30) to afford a yellowish powder [33–35].
1HNMR (CDCl3, 250 MHz) δ (ppm): 4.81 (s, 2H, −CH2-
CO-), 3.82 (s, 1H, SH), 7.89 (dd, 2H, J = 8.4 Hz, J = 2.4 Hz,
H5,6-Phthalimide), 7.94 (dd, 2H, J = 8.4 Hz, J = 2.4 Hz,
H5,6-Phthalimide), 13.81 (brs, NH). IR (KBr, cm
−1) ῡ:
3201, 3070, 2924, 1739, 1608, 1554, 1465, 1377, 1307,
1053, 717. MS (m/z, %): 320 (10), 287 (80), 263 (60), 231
(100), 160 (80), 159 (60), 121 (40), 104 (40), 76 (45).General procedure for synthesis of compounds 4a-4 l
In a flat bottom flask, 0.2 g (0.625 mmol) of 2-(1,3-dioxoi-
soindolin-2-yl)-N-(5-mercapto-1,3,4-thiadiazol-2-yl)aceta-
mide (compound 3) was treated with 0.035 g (0.625 mmol)
potassium hydroxide in absolute ethanol and heated for
5 min, then equimolar (0.625 mmol) quantity of appropri-
ate benzyl chloride derivative was added to the reaction
medium and reflux condition was performed for 24 h. Thin
layer chromatography (TLC) was carried out to determine
the reaction end. Then, crushed ice was added to the reac-
tion flask and the formed precipitate was filtered and col-
lected. Crystallization was performed using ethanol [35].2-(1,3-Dioxoisoindolin-2-yl)-N-(5-(2-nitrobenzylthio)-1,3,4-
thiadiazol-2-yl)acetamide (4a)
1HNMR (CDCl3, 250 MHz) δ (ppm): 4.79 (s, 2H, −S-
CH2-), 4.89 (s, 2H, −CH2-CO-), 7.45 (t, 1H, H4-2-Nitro-
phenyl), 7.57 (m, 2H, H5,6-2-Nitrophenyl), 7.81 (dd, 2H,
J = 8.4 Hz, J = 2.4 Hz, H5,6-Phthalimide), 7.95 (dd, 2H,
J = 8.4 Hz, J = 2.4 Hz, H5,6-Phthalimide), 8.06 (d, 1H,
J = 10 Hz, H3-2-Nitrophenyl). IR (KBr, cm
−1) ῡ: 3414,
3325, 3170, 3035, 2927, 2854, 2742, 1774, 1720, 1573,
1523, 1415, 1346, 1303, 1195, 952, 713.2-(1,3-Dioxoisoindolin-2-yl)-N-(5-(3-nitrobenzylthio)-1,3,4-
thiadiazol-2-yl)acetamide (4b)
1HNMR (CDCl3, 250 MHz) δ (ppm): 4.45 (s, 2H, −
S-CH2-), 4.77 (s, 2H, −CH2-CO-), 7.48-7.59 (m, 2H,
3-Nitrophenyl), 7.73 (dd, 2H, J = 8.4 Hz, J = 2.4 Hz, H5,6-
Phthalimide), 7.92 (d, 1H, J = 7.5 Hz, H4-3-Nitrophenyl),
8.24 (dd, 2H, J = 8.4 Hz, J = 2.4 Hz, H4,7-Phthalimide), 8.36
(s, 1H, H2-3-Nitrophenyl). IR (KBr, cm
−1) ῡ: 3429, 3209,
3066, 2924, 2854, 1774, 1708, 1527, 1411, 1350, 1296,
1195, 1053, 952, 717. MS (m/z, %): 455 (M+, Weak), 398
(15), 268 (100), 235 (35), 193 (45), 136 (55), 109 (15), 89
(30), 60 (35).2-(1,3-Dioxoisoindolin-2-yl)-N-(5-(4-nitrobenzylthio)-1,3,4-
thiadiazol-2-yl)acetamide (4c)
1HNMR (CDCl3, 250 MHz) δ (ppm): 4.42 (s, 2H, −S-
CH2-), 4.79 (s, 2H, −CH2-CO-), 7.52 (d, 2H, J = 10 Hz,
H2,6-4-Nitrophenyl), 7.79 (dd, 2H, J = 8.4 Hz, J = 2.4 Hz,
H5,6-Phthalimide), 7.91 (dd, 2H, J = 8.4 Hz, J = 2.4 Hz,
H4,7-Phthalimide), 8.2 (d, 2H, J = 10 Hz, H2,6-4-Nitro-
phenyl). IR (KBr, cm−1) ῡ: 3421, 3352, 3113, 2927, 2850,
1774, 1720, 1519, 1415, 1346, 1303, 1107, 952, 713. MS
(m/z, %): 455 (M+, Weak), 398 (12), 268 (100), 235 (20),
193 (90), 136 (30), 109 (25), 89 (60), 60 (40).2-(1,3-Dioxoisoindolin-2-yl)-N-(5-(3-methoxybenzylthio)-
1,3,4-thiadiazol-2-yl)acetamide (4d)
1HNMR (CDCl3, 250 MHz) δ (ppm): 3.74 (s,
3H, −OCH3), 4.38 (s, 2H, −S-CH2-), 4.86 (s, 2H, −CH2-
CO-), 6.77 (d, 1H, J = 10 Hz, H4-3-Methoxyphenyl), 6.92
(m, 2H, H2, H6 -3-Methoxyphenyl), 7.20 (t, 1H, J = 7.5 Hz,
H5-3-Methoxyphenyl), 7.77 (dd, 2H, J = 8.4 Hz, J = 2.4 Hz,
H5,6-Phthalimide), 7.92 (dd, 2H, J = 8.4 Hz, J = 2.4 Hz,
H4,7-Phthalimide). IR (KBr, cm
−1) ῡ: 3425, 3329, 3170,
3035, 2927, 2850, 1720, 1624, 1577, 1415, 1303, 1269,
1159, 1049, 952, 713. MS (m/z, %): 440 (M+, 10), 160
(40), 121 (100), 104 (45), 92 (20), 76 (35), 65 (60), 52 (55).2-(1,3-Dioxoisoindolin-2-yl)-N-(5-(4-methoxybenzylthio)-
1,3,4-thiadiazol-2-yl)acetamide (4e)
1HNMR (CDCl3, 250 MHz) δ (ppm): 3.76 (s, 3H, −OCH3),
4.35 (s, 2H, −S-CH2-), 4.85 (s, 2H, −CH2-CO-), 6.82 (d,
2H, J = 7.5 Hz, H3,5-4-Mehoxyphenyl), 7.28 (d, 2H,
J = 7.5 Hz, H2,6-4-Mehoxyphenyl), 7.77 (dd, J = 8.4 Hz,
J = 2.4 Hz, 2H, H5,6-Phthalimide), 7.92 (dd, 2H, J = 8.4 Hz,
J = 2.4 Hz, H5,6-Phthalimide). IR (KBr, cm
−1) ῡ: 3325, 3248,
3132, 3035, 2927, 2850, 1774, 1705, 1627, 1577, 1419,
1307, 1246, 1195, 1180, 1064, 952. MS (m/z, %): 440
(M+, Weak), 249 (10), 193 (10), 160 (60), 121 (100), 104
(30), 92 (40), 76 (75), 65 (70), 52 (45).
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thiadiazol-2-yl)acetamide (4f)
1HNMR (CDCl3, 250 MHz) δ (ppm): 4.47 (s, 2H, S-CH2-),
4.83 (s, −CH2-CO-), 7.04-7.09 (m, 4H, 2-Fluorophenyl),
7.79 (dd, 2H, J = 8.4 Hz, J = 2.4 Hz, H5,6-Phthalimide), 7.91
(dd, 2H, J = 8.4 Hz, J = 2.4 Hz, H4,7-Phthalimide). IR
(KBr, cm−1) ῡ: 3429, 3329, 3170, 2924, 2854, 2738,
1774, 1720, 1624, 1573, 1492, 1415, 1303, 1195, 952,
759. MS (m/z, %): 428 (M+, 12), 371 (25), 241 (20), 166
(30), 109 (100), 83 (10).
2-(1,3-Dioxoisoindolin-2-yl)-N-(5-(3-fluorobenzylthio)-1,3,4-
thiadiazol-2-yl)acetamide (4 g)
1HNMR (CDCl3, 250 MHz) δ (ppm): 4.39 (s, 2H, −S-
CH2-), 4.85 (s, 2H, −CH2-CO-), 6.92 (t, 1H, J = 7.5 Hz,
H5-3-Fluorophenyl), 7.11 (m, 2H, H4, H6 -3-Fluorophe-
nyl), 7.24 (m, 1H, H2-3-Fluorophenyl), 7.77 (dd, 2H, J =
8.4 Hz, J = 2.4 Hz, H5,6-Phthalimide), 7.92 (dd, 2H, J =
8.4 Hz, J = 2.4 Hz, H5,6-Phthalimide), 13.70 (brs, NH). IR
(KBr, cm−1) ῡ: 3444, 3170, 3035, 2924, 2854, 1774, 1720,
1566, 1415, 1300, 952, 713. MS (m/z, %): 428 (M+, 15),
371 (30), 241 (40), 166 (25), 109 (100), 83 (10).
2-(1,3-Dioxoisoindolin-2-yl)-N-(5-(4-fluorobenzylthio)-1,3,4-
thiadiazol-2-yl)acetamide (4 h)
1HNMR (CDCl3, 250 MHz) δ (ppm): 4.36 (s, 2H, −S-
CH2-), 4.86 (s, 2H, −CH2-CO-), 6.99 (t, 2H, H2,6-4-
Fluorophenyl), 7.32 (t, 2H, H3,5-4-Fluorophenyl), 7.77
(dd, 2H, J = 8.4 Hz, J = 2.4 Hz, H5,6-Phthalimide), 7.92
(dd, 2H, J = 8.4 Hz, J = 2.4 Hz, H4,7-Phthalimide). IR
(KBr, cm−1) ῡ: 3433, 3329, 3159, 3039, 2927, 2850, 1774,
1720, 1624, 1573, 1508, 1415, 1303, 1226, 1087, 952,
831, 713. MS (m/z, %): 428 (10), 371 (20), 241 (10), 166
(40), 109 (100), 83 (12).
N-(5-(2-Chlorobenzylthio)-1,3,4-thiadiazol-2-yl)-2-(1,3-
dioxoisoindolin-2-yl)acetamide (4i)
1HNMR (CDCl3, 250 MHz) δ (ppm): 4.54 (s, 2H, −S-
CH2-), 4.87 (s, 2H, −CH2-CO-), 7.20 (m, 2H, H3,6-2-
Chlorophenyl), 7.35 (t, 1H, H4-2-Chlorophenyl), 7.43
(t, 1H, H5-2-Chlorophenyl), 7.77 (dd, 2H, J = 8.4 Hz,
J = 2.4 Hz, H5,6-Phthalimide), 7.92 (dd, 2H, J = 8.4 Hz,
J = 2.4 Hz, H4,7-Phthalimide). IR (KBr, cm
−1) ῡ: 3475,
3429, 3170, 3051, 2927, 2858, 2738, 1774, 1720,
1566, 1469, 1415, 1300, 1195, 952, 713. MS (m/z, %):
446 (M++2, 4), 444 (M+, 10), 284 (12), 162 (10), 160
(85), 125 (100), 104 (10), 76 (15).
N-(5-(3-Chlorobenzylthio)-1,3,4-thiadiazol-2-yl)-2-(1,3-
dioxoisoindolin-2-yl)acetamide (4j)
1HNMR (CDCl3, 250 MHz) δ (ppm): 4.37 (s, 2H, −S-
CH2-), 4.85 (s, 2H, −CH2-CO-), 7.24 (m, 3H, 3-
Chlorophenyl), 7.41 (s, 1H, H2-3-Chlorophenyl), 7.77
(dd, 2H, J = 8.4 Hz, J = 2.4 Hz, H5,6-Phthalimide), 7.92(dd, 2H, J = 8.4 Hz, J = 2.4 Hz, H4,7-Phthalimide). IR
(KBr, cm−1) ῡ: 3325, 3170, 3055, 2927, 2850, 1720, 1627,
1573, 1400, 1300, 1203, 1111, 1083, 1049, 956, 713, 648.
MS (m/z, %): 446 (M++2, 5), 444 (M+, 15), 162 (25), 160
(50), 125 (100), 104 (30), 76 (35).N-(5-(4-Chlorobenzylthio)-1,3,4-thiadiazol-2-yl)-2-(1,3-
dioxoisoindolin-2-yl)acetamide (4 k)
1HNMR (CDCl3, 250 MHz) δ (ppm): 4.35 (s, 2H, −S-CH2-),
4.85 (s, 2H, −CH2-CO-), 7.28 (dd, 4H, 4-Chlorophenyl),
7.77 (dd, 2H, J = 8.4 Hz, J = 2.4 Hz, H5,6-Phthalimide), 7.91
(dd, 2H, J = 8.4 Hz, J = 2.4 Hz, H5,6-Phthalimide). IR (KBr,
cm−1) ῡ: 3325, 3155, 3059, 3035, 2927, 2850, 1774, 1720,
1627, 1573, 1492, 1303, 1091. MS (m/z, %): 446 (M++2, 5),
444 (M+, 12), 284 (5), 162 (15), 160 (90), 125 (100), 104
(20), 76 (25).N-(5-(Benzylthio)-1,3,4-thiadiazol-2-yl)-2-(1,3-
dioxoisoindolin-2-yl)acetamide (4 l)
1HNMR (CDCl3, 250 MHz) δ (ppm): 4.39 (s, 2H, −S-
CH2-), 4.86 (s, 2H, −CH2-CO-), 7.23-7.37 (m, 5H,
Phenyl), 7.77 (dd, 2H, J = 8.4 Hz, J = 2.4 Hz, H5,6-
Phthalimide), 7.92 (dd, 2H, J = 8.4 Hz, J = 2.4 Hz,
H4,7-Phthalimde). IR (KBr, cm
−1) ῡ: 3425, 3329, 3170,
3032, 2927, 2850, 1720, 1627, 1573, 1546, 1415,
1396, 1303, 1195, 1111, 952, 709. MS (410, M+), 160
(75), 91 (100), 77 (10).MTT assay
Synthesized derivatives (compounds 4a-4 l) were tested
for cytotoxic activity at 0.1-100 μM concentration in
three human cancer cell lines of PC3 (Prostate carcin-
oma), HT29 (Colorectal cancer) and SKNMC (Neuro-
blastoma). Cells were purchased from the Pasteur
Institute of Iran. Cells from different cell lines were
seeded in 96-well plates at the density of 8000–10,000
viable cells per well and incubated for 24 h to allow cell
attachment. The cells were then incubated for another
24 h with various concentrations of compounds 4a-4 l.
Cells were then washed in PBS, and 20 μL of MTT
(3–(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium
bromide solution (5 mg/mL) were added to each well.
An additional 4 h of incubation at 37 °C were done, and
then the medium was discarded. Dimethyl sulfoxide
(60 μL) was added to each well, and the solution was
vigorously mixed to dissolve the purple tetrazolium crys-
tals. The absorbance of each well was measured by plate
reader (Anthous 2020; Austria) at a test wavelength of
550 nm against a standard reference solution at 690 nm.
The amount of produced purple formazan is propor-
tional to the percentage of cell viability [33–35].
Table 1 Properties of synthesized compounds





2 - C10H7NO4 205.4 115 70
3 - C12H8N4O3S2 320.3 220 48
4a o-NO2 C19H13N5O5S2 455.4 179 39
4b m-NO2 C19H13N5O5S2 455.4 243 46
4c p-NO2 C19H13N5O5S2 455.4 204 74
4d m-OCH3 C20H16N4O4S2 440.5 186 43
4e p-OCH3 C20H16N4O4S2 440.5 259 41
4f o-F C19H13FN4O3S2 428.4 190 48
4 g m-F C19H13FN4O3S2 428.4 173 40
4 h p-F C19H13FN4O3S2 428.4 154 57
4i o-Cl C19H13ClN4O3S2 444.9 205 47
4j m-Cl C19H13ClN4O3S2 444.9 188 57
4 k p-Cl C19H13ClN4O3S2 444.9 155 45
4 l H C19H14N4O3S2 410.4 187 53
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The basis of this method is oxidative coupling of 3-
methyl-2-benzothiazolinone hydrazone (MBTH) with 3
(dimethylamino) benzoic acid (DMAB) in a hemoglobin
catalyzed reaction. This reaction is initiated in the pres-
ence of lipoxygenase reaction product, linoleic acid hy-
droperoxide and results in a blue color formation which
has a peak absorbtion at 590 nm [36]. Quercetin was
used as the reference compound. Linoleic acid and two
stock solutions (A and B) were prepared first. Solution A
contained 50 mM DMAB and l00 mM phosphate buffer
(pH = 7.0). Solution B was prepared by mixing 10 mM
MBTH (3 mL) and hemoglobin (5 mg/mL, 3 mL) in
50 mM phosphate buffer at pH 5.0 (25 mL). A linoleic
acid solution (1 mg/ml) was prepared by diluting 5 mg
linoleic acid (solubilised in 0.5 ml ethanol) with KOH
100 mM.
For each compound the samples were solved in etha-
nol (25 μl) and mixed in a test tube with SLO (4000
units/mL, prepared in 50 mM phosphate buffer pH =
7.0, 25 μL) and phosphate buffer (50 mM, pH = 7,
900 μL). After a 5 min delay at room temperature, 50 μL
linoleic acid was added to the mixture to start the
hydroperoxidation reaction. After 8 min, solution A
(270 μL) and solution B (130 μL) were added to the
above mixture. 5 min later, 200 μL of SDS solution (2 %)
was added to stop the reaction. The absorbance at
590 nm was compared with control (ethanol without
sample).
Docking
The related protein structure was downloaded from
brookhaven protein data bank (http://RCSB.org).
Namely, 15-Lipoxygenase-1 in complex with dihydroxy-
benzoic acid (pdb code: 1N8Q) was utilized. ArgusLab
software 4.0 was used for drawing the chemical struc-
tures and then energy minimization was carried out
using AM1 as semiemperical method [37]. The related
ligand groups as well as binding site groups were de-
fined. The binding location of dihydroxybenzoic aicd
was defined as binding site for searching the best pose
and conformation for all ligands. The geometry
optimization of the protein structure was done by uni-
versal force field (UFF) as molecular mechanic method.
Binding mode and related interactions of ligands with




According to the Table 1 all intermediate and final com-
pounds were prepared with an average yield. Compound
4a with ortho nitro moiety obtained with a low yield
(39 %) and compound 4c with para nitro moietyprepared with an acceptable yield (74 %). For affording
compound 2, phthalic anhydride was reacted with gly-
cine in the presence of triethylamine in toluene under
reflux conditions to perform a Gabriel reaction. The
white powder of compound 2 was treated with N-ethyl-
N-dimethylaminopropyl carbodiimide (EDC) and hydro-
xybenzotriazole (HOBt) in acetonitrile and after 30 min,
5-amino-1,3,4-thiadiazole-2-thiol was added to form an
amidic bond. The obtained thiol derivative was used for
synthesis of the final products 4a–4 l in alkaline
medium that generated by potassium hydroxide in
refluxing ethanol.
Synthesized compounds were characterized by spec-
troscopic methods such as 1H NMR, IR and MS and
corresponding melting points were also measured. Com-
pound 4a with ortho nitro moiety rendered the lowest
melting point (179 °C) among the final products and
compounds 4e with para methoxy group demonstrated
the highest melting point (259 °C) in these series. 1H
NMR spectra were acquired in deutrated chloroform
(CDCl3). In the most cases the acidic property of the
proton of the amidic bond (NH group) was caused to
not be appeared in the NMR spectra. Phthalimide group
as well as 1,3,4-thiadiazole ring function as electron
withdrawing groups and these have an important role in
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group.
Cytotoxicity evaluation
Three cancerous cell lines were used to test the antican-
cer activity of the final compounds 4a-4 l. PC3 (Prostate
carcinoma), HT29 (colorectal cancer) and SKNMC
(neuroblastoma) was cultured and intended derivatives
were assessed at concentration 0.1-100 μM and the ob-
tained results were compared to doxorubicin as refer-
ence drug. None of the tested compounds showed
superior cytotoxic effect than doxorubicin at tested con-
centrations towards the utilized cell lines. Generally
tested derivatives exerted a better cytotoxic activity
against HT29 cell line compared to other cell lines. PC3
and SKNMC cell lines were the most resistant cell lines
to the tested compounds. None of the introduced moi-
eties containing electron withdrawing groups and elec-
tron donating groups on the phenyl residue were
efficacious to produce a remarkable anticancer activity.
Enzymatic assay
An enzyme inhibitory assay was performed towards 15-
lipoxygenase-1 and obtained results were presented as
percent of inhibition and provided in Table 2. Unfortu-
nately, none of the tested derivatives demonstrated su-
perior inhibitory effect than quercetin as reference
compound and natural product inhibitor of the enzyme.
Compound 4d with meta positioning of the methoxy
moiety was the most potent inhibitor in this series (38 %
inhibition). Moving the position of the methoxy to the
para decreased the inhibitory effect of the compound
significantly as observed in compound 4e. NitroTable 2 Biological data of synthesized compounds. Results of the cy








4 g m-F 26
4 h p-F 35
4i o-Cl 17
4j m-Cl 18.5
4 k p-Cl NAa
4 l H 19
Doxorubicin - -
Quercetin - 100
a:The percent of inhibition was determined at 200 μM concentration
b:No activitycontaining derivatives (4a, 4b, 4c) and compound 4 k
with para positioning of the chlorine substituent did not
show any inhibitory activity against 15-lipoxygenase-1.
Molecular modeling
All prepared derivatives were docked by ArgusLab soft-
ware into the active site of 15-lipoxygenase-1. Com-
pound 4d (m-OCH3) as representative of synthesized
compounds in this series that showed a superior enzyme
inhibitory activity in enzymatic assay has been shown in
Fig. 1. Four hydrogen bonds were detected with Ser 582,
Ser 586 and Ala 587. One of the nitrogen atom of the
1,3,4-thiadiazole ring has participated in hydrogen bond-
ing interaction with Ser 582. Amino acid Ser 586 has
also formed two hydrogen bonding interactions with
oxygen of the methoxy group. The first one is with oxy-
gen atom of the hydroxyl group in the side chain of this
amino acid and the second one is with related NH2
group of the Ser 586. Finally, Ala 587 is responsible for
the fourth hydrogen bond interaction. The NH of the
amidic bond between Ala 587 and Ser 586 has the role
of hydrogen bond donor to the oxygen of the methoxy
group. This potential and probable hydrogen bonds
maybe a logical reason for higher enzyme inhibitory po-
tency of compound 4d compared to others.
Structure activity relationship
Enzyme inhibitory effect of the final prepared com-
pounds was investigated towards 15-lipoxygense-1 and
obtained results were listed in Table 2. None of the
tested derivatives exerted favorable inhibitory potency
towards 15-LOX-1 at 200 μM concentration compared
to quercetin as reference compound. Quercetin astotoxicity assay were reported as IC50 ± SD (μM)






100< 10.91 ± 4.1 100<
100< 100< 50.2 ± 5.4
88.83 ± 4.3 100< 100<
81.92 ± 4.7 100< 100<
89.21 ± 5.7 100< 100<
>100 24.06 ± 3.1 69.7 ± 3.6
>100 100< 100<
3.8 ± 0.75 2.1 ± 0.26 1.3 ± 0.4
- - -
Fig. 1 Structure of docked compound 4d (m-OCH3) into the active site of 15-lipoxygenase. Four hydrogen bonds were detected with Ser 582
(one), Ser 586 (two) and Ala 587 (one)
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at 200 μM concentration. Among the tested derivatives,
compound 4d with meta positioning of the methoxy
group afforded the highest inhibitory effect (38 %).
Movement of the methoxy to the para position caused a
detrimental effect and decreased the inhibitory activity.
Nitro containing compounds (4a, 4b, 4c) as well as para
chlorine containing compound (4 k) did not demon-
strated any inhibitory activity at tested concentration.
Fluorine containing derivatives also exhibited a high in-
hibitory activity compared to others. This inhibitory ac-
tivity was more observable while the fluorine substituted
at position ortho and para. It is probable that electron
withdrawing effect of this moiety is a critical factor to
increase the enzyme inhibitory effect. Replacement of
the fluorine substituent with chlorine caused a decrease
in activity. Chlorine atom has a greater size and lipophi-
licity than fluorine and it is likely that these parameters
induce a negative effect on interaction of the ligands to
the corresponding receptor.
Three cancerous cell lines were used to evaluate the
in vitro cytotoxicity potency of synthesized derivatives.
Unfortunately, tested compounds did not display a re-
markable activity against utilized cell lines (Table 2).
Only compounds 4f (ortho fluorine) and 4 k (para
chlorine) rendered an acceptable cytotoxic potency
against HT29 cell line. None of the nitro and methoxy
substituted derivatives exerted an inhibitory potency
(IC50) up to 100 μM concentration. Substitution of the
fluorine at meta position of the phenyl residue caused
an enhancement in cytotoxic activity towards SKNMC
cell line. Para positioning of the fluorine was also
caused a brief increase in anticancer activity in PC3 cell
line. A descending trend in IC50 was seen from com-
pound 4i (o-Cl) to 4 k (p-Cl) against PC3 cell line. But,
a reverse trend was demonstrated for chlorinatedderivatives against HT29 and SKNMC cell lines. Steric
factor and lipophilicity effects produced by chlorine
atom maybe a probable reason for this observation.
Based on the above mentioned information, there is
not any direct correlation between the cytotoxic activity
and inhibition of lipoxygenase. According to the previ-
ously reported literature [34, 35], it could be hypothesized
that inhibition of tyrosine kinases is the probable of cyto-
toxicity of these compounds.Conclusions
A new series of compounds with combination of 1,3,4-
thiadiazole and phthalimide substructures were synthe-
sized and their cytotoxicity was evaluated in vitro using
MTT protocol. Furthermore, synthesized derivatives
were tested in an enzymatic assay for exploration of the
inhibitory activity towards 15-lipoxygenase-1. According
to the obtained results in MTT assay as well as enzym-
atic experiment, the investigated compounds did not
show a favorable anticancer activity. Amongst them, only
compounds 4f (ortho fluorine) and 4 k (para chlorine)
exhibited an acceptable cytotoxic potency towards HT29
cell line. Hence, further structural modifications are
needed to achieve derivatives with superior activity.
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